Harmony Revenue Growth Accelerates as Wakix Sets Record
Harmony kept its 2026 Wakix revenue forecast at $1.0 billion to $1.04 billion.
Harmony Biosciences Holdings (HRMY), the pharmaceutical company focused on neurological disorders, said Wakix revenue growth accelerated to 30% in the second quarter as the treatment delivered record sales.
Preliminary Wakix net revenue reached approximately $261 million, rebounding 21% from $215.4 million in the first quarter. The result reversed the sequential decline from $243.8 million in the fourth quarter and exceeded that level by about $17.2 million.
The year-over-year growth rate marked a shift in the drug’s recent trajectory. Wakix revenue had risen 17% in the first quarter and 21% in the fourth quarter before accelerating in the latest period.
Harmony reaffirmed its full-year 2026 Wakix net revenue guidance, maintaining the range issued with its fourth-quarter results and reiterated in April and May.
The announcement provided preliminary revenue only. Harmony scheduled its full second-quarter financial results and business update for Aug. 4, when it plans to report earnings and other measures including costs, margins, operating expenses, cash and patient counts.
The company also said Chief Financial Officer Glenn Reicin stepped down effective July 16, about three months after his appointment. Controller Stephen Mollichella became interim principal financial officer while Harmony searches for a permanent CFO, leaving the leadership transition in place ahead of the full quarterly report.